Home / Products / Pharma / General / By Brand Name / Gen-4
Cefepime Hydrochloride USP
Gen4 (Cefepime) is a fourth generation Cephalosporin antibiotic, having extended spectrum activity against gm (+) and gm (-) microbes as compares to third generation and additionally Cefepime may eradicate pathogens resistant to other Cephalosporin. Cefepime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Within the bacterial cells, the molecular targets of Cefepime are the penicillin binding proteins (PBPs). The chemical structure of Cefepime allows it to bind to penicillin binding proteins and to penetrate through outer membrane of Gm (-) bacteria more rapidly than most Cephalosporin. Cefepime is also more stable to beta-lactamase hydrolysis, making for an enhanced resistance pattern, especially with Gm (-) bacteria.
Gen4 - 500 mg IV/IM injection: Each vial contains Cefepime 500 mg (As sterile Cefepime HCl USP with L- Arginine). Gen4-1g IV/IM injection: Each vial contains Cefepime 1g (As sterile Cefepime HCl USP with L- Arginine).
Indications And Uses
In moderate to severe pneumonia, in mild to moderate uncomplicated/complicated urinary tract infection, in severe uncomplicated/complicated urinary tract infection, in moderate to severe uncomplicated skin and skin structure infections, in complicated intra-abdominal infections
Dosage And Administration
Adult dosage: Recommended dosage schedule for normal renal function - in moderate to severe pneumonia: 1-2g IV 12 hourly for 10 days; in empiric therapy for febrile neutropenic patients: 2g IV 8 hourly for 7 days; in mild to moderate uncomplicated/complicated urinary tract infection: 0.5 - 1g IV/IM 12 hourly for 7-10 days; in severe uncomplicated/complicated urinary tract infection: 2g IV, 12 hourly for 10 days, in moderate to severe uncomplicated skin and skin structure infections: 2g IV 12 hourly for 10 days; in complicated intra-abdominal infection: 2g IV (with Metronidazole) - 12 hourly for 7-10 days, Paediatric dosage: 50 mg /kg/dose 12 hourly (in neutropenic 8 hourly). Paediatric dose should not exceed that recommended for adults. Impaired hepatic function- No dose adjustment is necessary for patients with impaired hepatic function.
Rash, diarrhoea, nausea, vomiting, pruritis, fever and headache. Hypocalemia is more common among elderly patients. Serious adverse events including encephalopathy, myoclonus seizures and or renal failure have been reported in patients with renal impairment.
Cefepime should be prescribed with caution in individuals with a history of gastrointestinal particularly colitis. In patients with impaired renal function the dose of Cefepime should be adjusted. In pregnancy: Since, no adequate and well controlled studies of Cefepime use in pregnancy, so this drug should be used in pregnancy only if clearly needed. Paediatric use: It may be given over 2 month old aged child. Geriatric use: Older patients having renal insufficiency dosage and administration of Cefepime should be adjusted.
Cefepime is contraindicated in patients who have shown hypersensitive reaction to Cefepime or other Cephalosporin, Penicillins or other beta-Lactam antibiotics.
Gen4-500 mg IV/IM injection: Each vial contains Cefepime 500 mg (As sterile Cefepime HCl USP with L- Arginine) and a 5 ml ampoule sterile WFI for reconstitution in a combipack. Gen4-1g IV/IM injection: Each vial contains Cefepime 1g (As sterile Cefepime HCl USP with L- Arginine) and a 10 ml ampoule sterile WFI for reconstitution in a combipack.